OCUGEN CEO Sells 468k Shares at $1.12: Investor Impact and Outlook
OCUGEN CEO’s large share sale at a modest premium shows a disciplined Rule 10b‑5 plan, balanced by insider buying and optimism on regenerative cartilage breakthroughs. Investors should focus on clinical milestones and regulatory progress for future …
3 minutes to read